JP2013500712A - 逆遺伝学系 - Google Patents

逆遺伝学系 Download PDF

Info

Publication number
JP2013500712A
JP2013500712A JP2012522275A JP2012522275A JP2013500712A JP 2013500712 A JP2013500712 A JP 2013500712A JP 2012522275 A JP2012522275 A JP 2012522275A JP 2012522275 A JP2012522275 A JP 2012522275A JP 2013500712 A JP2013500712 A JP 2013500712A
Authority
JP
Japan
Prior art keywords
virus
construct
bacterial
segments
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012522275A
Other languages
English (en)
Japanese (ja)
Inventor
フィリップ ドルミッチャー，
ミシェル フランティ，
ピーター メイソン，
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013500712A publication Critical patent/JP2013500712A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2012522275A 2009-07-31 2010-07-30 逆遺伝学系 Withdrawn JP2013500712A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27315109P 2009-07-31 2009-07-31
US61/273,151 2009-07-31
PCT/IB2010/002137 WO2011012999A1 (en) 2009-07-31 2010-07-30 Reverse genetics systems

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2015215655A Division JP2016019547A (ja) 2009-07-31 2015-11-02 逆遺伝学系
JP2017146473A Division JP6666311B2 (ja) 2009-07-31 2017-07-28 逆遺伝学系

Publications (1)

Publication Number Publication Date
JP2013500712A true JP2013500712A (ja) 2013-01-10

Family

ID=43018886

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012522275A Withdrawn JP2013500712A (ja) 2009-07-31 2010-07-30 逆遺伝学系
JP2015215655A Pending JP2016019547A (ja) 2009-07-31 2015-11-02 逆遺伝学系
JP2017146473A Active JP6666311B2 (ja) 2009-07-31 2017-07-28 逆遺伝学系

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015215655A Pending JP2016019547A (ja) 2009-07-31 2015-11-02 逆遺伝学系
JP2017146473A Active JP6666311B2 (ja) 2009-07-31 2017-07-28 逆遺伝学系

Country Status (8)

Country Link
US (2) US9821052B2 (enExample)
EP (1) EP2459722B1 (enExample)
JP (3) JP2013500712A (enExample)
KR (1) KR20120039047A (enExample)
CN (2) CN102666860B (enExample)
AU (1) AU2010277310B2 (enExample)
CA (1) CA2769673A1 (enExample)
WO (1) WO2011012999A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101323582B1 (ko) * 2011-03-17 2013-10-30 충북대학교 산학협력단 Ｖｅｒｏ 세포 유래의 ｐｏｌⅠ 프로모터 및 이를 포함하는 재조합 벡터
US20130217071A1 (en) 2011-12-30 2013-08-22 Luz Montesclaros Methods and compositions for performing nucleic acid amplification reactions
ES2628301T3 (es) 2012-03-02 2017-08-02 Seqirus UK Limited Recombinación de virus de gripe
AU2013354219A1 (en) 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren
US20140274806A1 (en) 2013-03-15 2014-09-18 Synthetic Genomics Vaccines Influenza virus reassortment
MX2015009330A (es) * 2013-01-23 2016-04-15 Novartis Ag Reordenamiento del virus de influenza.
HK1218511A1 (zh) 2013-03-13 2017-02-24 Novartis Ag 乙型流感病毒重配
US10434166B2 (en) 2013-03-15 2019-10-08 University Of Maryland, College Park Methods and compositions for in vivo immune stimulation and antigen production
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
JP2016521553A (ja) 2013-06-06 2016-07-25 ノバルティス アーゲー インフルエンザウイルス再集合
PT3274447T (pt) * 2015-03-27 2020-01-21 Cadila Healthcare Ltd Vacina baseada no vírus da papeira recombinante jeryl lynn 2
US10726110B2 (en) * 2017-03-01 2020-07-28 Seven Bridges Genomics, Inc. Watermarking for data security in bioinformatic sequence analysis
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN114040979B (zh) * 2019-06-21 2024-06-28 国立大学法人大阪大学 稳定地保持外源基因的人工重组rna病毒的制作方法
CN110305854B (zh) * 2019-07-18 2023-09-15 山东中医药大学 一种携带荧光素酶的重组h3n2亚型流感病毒、构建方法及应用
US12576146B2 (en) 2019-11-18 2026-03-17 Seqirus UK Limited Method for producing reassortant influenza viruses
CN114395568A (zh) * 2021-10-29 2022-04-26 扬州大学 一种猪流行性腹泻病毒感染性cDNA克隆及其构建方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520573A (ja) * 1999-07-14 2003-07-08 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー 分節化した（−）鎖ＲＮＡウイルスのｉｎｖｉｔｒｏ再構築
WO2004022760A1 (en) * 2002-09-04 2004-03-18 Polymun Scientific Immunbiologische Forschung Gmbh Generation of recombinant influenza virus using baculovirus delivery vector
JP2008520248A (ja) * 2004-11-19 2008-06-19 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション タンデム転写ユニットを有する組換えインフルエンザベクター
WO2009000891A2 (en) * 2007-06-27 2008-12-31 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6274147B1 (en) * 1998-03-31 2001-08-14 University Of Maryland-Biotechnology Institute Method for generating nonpathogenic infectious pancreatic necrosis virus (IPNV) from synthetic RNA transcripts
DK2316923T3 (en) 1998-06-12 2018-01-08 Icahn School Med Mount Sinai Attenuated influenza viruses with altered interferon antagonist activity for use as vaccines and drugs
EP1098961B1 (en) 1998-06-12 2008-01-16 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
AR025750A1 (es) 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
WO2001064846A1 (fr) 2000-03-03 2001-09-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule
CN100489107C (zh) 2000-04-28 2009-05-20 圣朱德儿童研究医院 用于产生感染性流感病毒的dna转染系统
US6593111B2 (en) * 2000-05-21 2003-07-15 University Of North Carolina At Chapel Hill Directional assembly of large viral genomes and chromosomes
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
WO2005097181A1 (en) 2004-04-05 2005-10-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
US20080254067A1 (en) 2004-05-20 2008-10-16 Id Biomedical Corporation Process for the Production of an Influenza Vaccine
CN103555670B (zh) 2004-12-23 2015-08-12 米迪缪尼有限公司 用于病毒增殖的非致瘤性mdck细胞系
DK1831357T3 (da) 2004-12-24 2012-12-10 Abbott Biologicals Bv Genvinding af influenzavirus
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CA2613283A1 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
ES2359214T5 (es) 2005-11-01 2014-10-08 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual por tratamiento con beta-propiolactona
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
JP5491173B2 (ja) 2006-04-19 2014-05-14 メディミューン，エルエルシー イヌ細胞中でマイナス鎖ウイルスｒｎａを発現させるための方法および組成物
PT2086582E (pt) 2006-10-12 2013-01-25 Glaxosmithkline Biolog Sa Vacina compreendendo uma emulsão adjuvante óleo em água
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
CA2701923C (en) * 2007-10-08 2018-07-10 Synthetic Genomics, Inc. Assembly of large nucleic acids
CN101302499A (zh) * 2008-06-30 2008-11-12 中国科学院广州生物医药与健康研究院 一种流感病毒疫苗种子株的制备方法
EP2233568A1 (en) * 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520573A (ja) * 1999-07-14 2003-07-08 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー 分節化した（−）鎖ＲＮＡウイルスのｉｎｖｉｔｒｏ再構築
WO2004022760A1 (en) * 2002-09-04 2004-03-18 Polymun Scientific Immunbiologische Forschung Gmbh Generation of recombinant influenza virus using baculovirus delivery vector
JP2008520248A (ja) * 2004-11-19 2008-06-19 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション タンデム転写ユニットを有する組換えインフルエンザベクター
WO2009000891A2 (en) * 2007-06-27 2008-12-31 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014045806; Ｊｏｕｒｎａｌ　ｏｆ　Ｖｉｒｏｌｏｇｙ Ｖｏｌ．８３，　Ｎｏ．１８, 20090708, ｐ．９２９６-９３０３ *
JPN6014045807; Ｊｏｕｒｎａｌ　ｏｆ　Ｖｉｒｏｌｏｇｙ Ｖｏｌ．７６，　Ｎｏ．２１, 2002, ｐ．１１０６５-１１０７８ *

Also Published As

Publication number Publication date
JP6666311B2 (ja) 2020-03-13
KR20120039047A (ko) 2012-04-24
WO2011012999A1 (en) 2011-02-03
US20180236058A1 (en) 2018-08-23
JP2017189179A (ja) 2017-10-19
JP2016019547A (ja) 2016-02-04
EP2459722B1 (en) 2017-09-06
EP2459722A1 (en) 2012-06-06
US9821052B2 (en) 2017-11-21
CN102666860A (zh) 2012-09-12
AU2010277310B2 (en) 2015-01-15
HK1175814A1 (en) 2013-07-12
CA2769673A1 (en) 2011-02-03
US20120270321A1 (en) 2012-10-25
CN102666860B (zh) 2015-06-17
US10610584B2 (en) 2020-04-07
AU2010277310A1 (en) 2012-02-23
CN104862335A (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
JP6666311B2 (ja) 逆遺伝学系
US10358630B2 (en) Recombinant influenza vectors with tandem transcription units
JP6279503B2 (ja) インフルエンザウイルスの再集合
JP5836266B2 (ja) 非内因性ｐｏｌＩプロモーターを使用した逆遺伝学
JP2016104004A (ja) ウイルスレスキューのための改善された逆遺伝学
JP2016506724A (ja) インフルエンザウイルスの再集合
KR20110101137A (ko) Ｒｎａ 바이러스의 생성을 위한 신규한 방법
AU2015201871A1 (en) Reverse genetics systems
HK1175814B (en) Reverse genetics systems
HK1171786B (en) Reverse genetics systems
HK1171786A (en) Reverse genetics systems

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151102

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151224

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170629

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20170810

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170914

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170929